NORTH CHICAGO, Ill., April 17, 2019 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting applications for the 2019-2020 academic school year. Undergraduate and graduate students are invited to apply for the scholarship until May 29, 2019 at 11:00 a.m. U.S. eastern time by visiting www.AbbVieCFScholarship.com. Students can apply online or by downloading an application on the scholarship website.
NORTH CHICAGO, Ill., April 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.
NORTH CHICAGO, Ill., March 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI™ (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies. This approval marks the first country approval in the world for SKYRIZI.
NORTH CHICAGO, Ill., March 21, 2019 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $40 million to North Chicago Community Unit School District (CUSD) 187 to fund the rebuilding of the district's only middle school: Neal Math & Science Academy. This donation will provide a safer, modernized learning environment to improve student success for children and aims to help improve graduation rates, reduce dropout rates and increase college and career readiness.
NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax (VENCLEXTA®/VENCLYXTO®) for the investigational treatment of multiple myeloma. The partial clinical hold follows a review of data from the ongoing Phase 3 BELLINI trial (M14-031), a study in relapsed/refractory multiple myeloma, in which a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial. As a result of this action, no new patients should be enrolled in any studies of venetoclax for multiple myeloma until a further analysis of the data is completed. Patients who are currently enrolled in studies and receiving benefit from the therapy may continue with treatment, after consultation with their physician.
NORTH CHICAGO, Ill., March 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) to venetoclax, for use in combination with obinutuzumab as a fixed duration investigational combination, for untreated adult patients with chronic lymphocytic leukemia (CLL). According to the FDA, this designation is intended to expedite the review of therapies for serious or life-threatening conditions. The designation coincides with the completion of the supplemental New Drug Application (sNDA) submission to the FDA for approval in previously-untreated CLL patients.
NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019. Michael Severino, vice chairman and president, will present at 9:15 a.m. Central time.
NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for SKYRIZI™ (risankizumab), an investigational interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
NORTH CHICAGO, Ill., Feb. 28, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 39th Annual Cowen Health Care Conference on Tuesday, March 12, 2019. Richard A. Gonzalez, chairman and chief executive officer, will present at 7:00 a.m. Central time.
NORTH CHICAGO, Ill., Feb. 25, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present 19 abstracts during the 2019 American Academy of Dermatology (AAD) Annual Meeting, March 1-5, in Washington, D.C., including new data from the psoriasis pivotal trials for risankizumab, an investigational interleukin-23 (IL-23) inhibitor.
Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.
Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?
